Cellectis
  • About
    Our mission
    Governance
    Partners
  • Science
    Our Genome Engineering Platform
    TALEN® Technology
    In-House Manufacturing
  • Pipeline
    Product Candidates
  • Investors
    IR Overview
    News
    • Press releases
    • Events and Webcasts
    Presentations
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    Corporate Governance
    • Board of Directors
    • Executive Committee
    • External Auditors
    • Governance Documents
    • General meetings
    Financial Information
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    Shareholders Services
    • IR Inquiries
    • IR FAQ
  • Careers
    Our culture
    Job opportunities
  • Contact us
LinkedinX FR
› Investors › Scientific presentations
  • About
    • Our mission
    • Governance
    • Partners
  • Science
    • Our Genome Engineering Platform
    • TALEN® Technology
    • In-House Manufacturing
  • Pipeline
    • Product Candidates
  • Investors
    • IR Overview
    • News
      • Press releases
      • Events and Webcasts
    • Presentations
      • Corporate presentations
      • Scientific presentations
      • Scientific publications
    • Corporate Governance
      • Board of Directors
      • Executive Committee
      • External Auditors
      • Governance Documents
      • General meetings
    • Financial Information
      • SEC filings
      • Financial statements
      • Voting Rights & Share Capital
      • Stock information
    • Shareholders Services
      • IR Inquiries
      • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
  • Contact us
FR
LinkedinX

Scientific presentations

All 2026 2025 2024 2023 2022 2021
8
Dec 2025
06:30 E.S.T.

Trial In Progress: Open-Label Dose-Finding and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART20x22 in Subjects with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL) NatHali-01 – ASH 2025

Download the PDF file
8
Dec 2025
06:30 E.S.T.

Increased Alemtuzumab Exposure Correlates with Improved Responses in Heavily Pretreated r/r ALL patients: analysis of the BALLI-01 trial – ASH 2025

Download the PDF file
7
Oct 2025
06:40 E.S.T.

Circularization of Single-Stranded DNA Donor Template Unleashes the Power of Non-Viral Gene Delivery for Long-Term HSCs editing – ESGCT 2025

Download the PDF file
7
Oct 2025
06:40 E.S.T.

Comprehensive Analysis of TALEB Off-target Editing – ESGCT 2025

Download the PDF file
13
May 2025
12:25 E.S.T.

High-fidelity C-to-T editing with TALE base editors – ASGCT 2025

Download the PDF file
13
May 2025
08:17 E.S.T.

TALEN®- Mediated non-viral Transgene Insertion for the Advancement of Cellular and Gene Therapies – ASGCT 2025

Download the PDF file
24
Feb 2025
12:30 E.S.T.

CAR induced expression of synthetically engineered FAP-IL2v immunocytokine boosts persistent anti-tumor activity of TALEN®-edited allogeneic CAR T-cells without associated IL-2 toxicity

Download the PDF file

Scientific publications

Discover Cellectis' scientific publications

Learn more
cellectis

Clinical-stage biotech · Dual-listed on Nasdaq (CLLS) and Euronext Growth (ALCLS).
Paris · New York · Raleigh.

  • ABOUT
    • Our mission
    • Governance
    • Partners
  • SCIENCE
    • Our Genome Engineering Platform
    • TALEN® Technology
    • In-House Manufacturing
  • PIPELINE
    • Product Candidates
  • INVESTORS
    • Events
    • Corporate presentations
    • Scientific presentations
    • Scientific publications
    • Governance Documents
    • ESG report
    • Shareholders Meetings
    • SEC filings
    • Financial statements
    • Voting Rights & Share Capital
    • Stock information
    • PDMR Notifications
    • IR Inquiries
    • IR FAQ
  • Careers
    • Our culture
    • Job opportunities
© 2026 Cellectis — All rights reserved
  • Legal notice
  • Community Guidelines